Clin2
NCT07263139Possibly a fitRecruiting

Testing AGP100 for CPVT heart condition

Catecholaminergic Polymorphic Ventricular Tachycardia

Part of Heart & circulation clinical trials.

This trial tests a new drug called AGP100 for people with CPVT, a genetic heart condition that causes dangerous heartbeats during exercise. The goal is to see if AGP100 can safely reduce these abnormal heart rhythms.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
10 people
Ages
18 years to 75 years
Study type
Interventional

Who can take part

  • You must be between 18 and 75 years old.
  • You must have a confirmed diagnosis of CPVT caused by an RYR2 genetic change.
  • Your heart should produce extra beats during exercise (shown on a bike stress test).
  • You must be on a stable, best-tolerated dose of a beta-blocker (like propranolol or nadolol) for at least 4 weeks before the study starts.
  • You need to avoid new or very hard exercise for 24 hours before each study visit.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06658899Recruiting· Phase 2
Study of CRD-4730 for CPVT (rare heart rhythm disorder)

This study tests an experimental drug called CRD-4730 for people with CPVT, a rare inherited heart rhythm disorder that can cause dangerous fast heartbeats during exercise or stress. The trial will see if the drug can help control these abnormal heart rhythms better than current treatments.

San Francisco, California
NCT07148089Recruiting· Phase 1
Gene therapy study for CPVT heart condition

This trial tests a new gene therapy called SGT-501 for people with a genetic heart condition called CPVT, which can cause dangerous fast heartbeats. The goal is to see if the treatment can reduce these episodes.

Boston, Massachusetts
NCT06575881Recruiting
Genetic heart muscle disease and heart rhythm study

This study looks at the risk of a fast heart rhythm (ventricular tachycardia) in people with genetic heart muscle diseases. It tests whether having a specific genetic change affects the success of a heart ablation procedure.

Nashville, Tennessee
NCT06205550Not yet recruiting· Phase 2
N-of-1 trial for Andersen-Tawil syndrome and MEPPC

This trial tests personalized medication strategies for people with Andersen-Tawil syndrome (ATS) or a specific type of heart condition called MEPPC. It aims to find the safest and most effective treatment for managing heart rhythm issues.

NCT06922994Recruiting· Phase 2
Testing atorvastatin for arrhythmogenic cardiomyopathy

This trial tests if a common cholesterol medicine, atorvastatin, can slow the progression of arrhythmogenic cardiomyopathy, a genetic heart condition that can cause abnormal heart rhythms. If you have this condition, joining this study may help researchers find a new way to protect your heart.

Pavia, PV
NCT06661278Recruiting
Exercise testing in kids with inherited heart rhythm conditions

This study looks at how children with certain genetic heart rhythm problems, like long QT syndrome, respond to exercise. It may help doctors understand how to better manage these conditions.

London

Hear when a new Catecholaminergic Polymorphic Ventricular Tachycardia trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.